百迪爾成立于年11月重組后成為新偉方的全資控股子公司，新偉方作為新的研發(fā)主體全面實(shí)施公司的業(yè)務(wù)運(yùn)行。公司擁有近1000平米的研發(fā)和辦公場所，以及百家匯提供的近萬平方米的公共服務(wù)區(qū)域。
新偉方&百迪爾是由醫(yī)藥行業(yè)經(jīng)驗(yàn)豐富、充滿激情和活力的創(chuàng)業(yè)團(tuán)隊(duì)組成的小分子藥物研發(fā)公司，公司擁有近40人的專業(yè)研發(fā)團(tuán)隊(duì)和外部顧問團(tuán)隊(duì)，立足于創(chuàng)新藥物和仿制藥物的項(xiàng)目研發(fā)管線的建設(shè)和累積，管理團(tuán)隊(duì)具有國內(nèi)仿制藥、專利藥物和國際項(xiàng)目合作研發(fā)以及項(xiàng)目立項(xiàng)評估等豐富的工作經(jīng)驗(yàn)，具備成功研發(fā)小分子藥物到產(chǎn)品上市的實(shí)戰(zhàn)經(jīng)驗(yàn)，具有從實(shí)驗(yàn)室工藝路線設(shè)計(jì)和優(yōu)化到工業(yè)化放大生產(chǎn)的成功經(jīng)驗(yàn)和研發(fā)理念。
公司藥物研發(fā)基礎(chǔ)設(shè)施齊全，同時(shí)享有百家匯分析測試中心平臺提供的大型進(jìn)口先進(jìn)儀器設(shè)備和高效快捷的服務(wù)，包括化合物理化性質(zhì)測定、分離純化及結(jié)構(gòu)鑒定等專業(yè)分析測試服務(wù)，以及創(chuàng)新藥物研發(fā)技術(shù)平臺：抗體藥物平臺、生物評價(jià)平臺、分析測試中心、實(shí)驗(yàn)動(dòng)物中心、CRO聯(lián)盟等，可完成小分子和生物藥物全流程研發(fā)。
公司發(fā)展目標(biāo)：公司信奉 “研發(fā)是成功的基石，創(chuàng)新展現(xiàn)價(jià)值”。公司圍繞“一切以項(xiàng)目為核心”，以產(chǎn)品獲批上市為研發(fā)目標(biāo)，以國際主流創(chuàng)新體系和仿制藥質(zhì)量體系為標(biāo)桿，打造公司自身的項(xiàng)目研發(fā)管線，在某些治療領(lǐng)域形成若干上市產(chǎn)品，重點(diǎn)涉足心腦血管、精神神經(jīng)、炎癥、抗病毒和腫瘤五大疾病治療領(lǐng)域。
公司核心業(yè)務(wù)：自研和外部合作相結(jié)合，建立豐富的和不同階段的項(xiàng)目研發(fā)管線。公司發(fā)展以生存為基礎(chǔ)，在項(xiàng)目累積階段，承接不同形式的項(xiàng)目合作，包括技術(shù)轉(zhuǎn)讓，定制開發(fā)，共同合作開發(fā)等?，F(xiàn)已建立若干商務(wù)合作伙伴，以及原料委托生產(chǎn)定點(diǎn)企業(yè)
公司堅(jiān)持以人為本，以項(xiàng)目為核心，作為公司持續(xù)和快速發(fā)展的源動(dòng)力；公司遵循德才兼?zhèn)洹⒁缘聻橄鹊挠萌藰?biāo)準(zhǔn)；公司貫徹誠信、敬業(yè)、協(xié)作、進(jìn)取的職業(yè)素養(yǎng)；公司以創(chuàng)造具有高附加值和商機(jī)的產(chǎn)品為導(dǎo)向；最終以實(shí)現(xiàn)公司與個(gè)人價(jià)值共贏作為共同發(fā)展目標(biāo)。
公司業(yè)務(wù)拓展： 2015年啟動(dòng)參股或控股技術(shù)和產(chǎn)品依托本公司的原料藥生產(chǎn)企業(yè)，誠邀有共同發(fā)展目標(biāo)的企業(yè)合作。
About Newelpharm & Biodeal
Newelpharm & Biodeal was established in 2012. Targeting at novel small molecule drug development, Newelpharm & Biodeal has rich experience in pharmaceutical development from pre-IND to NDA.  Our top management team is composed of western-trained professionals, and they all have multiple years of working experience in global pharmaceutical and biotech companies. Our business is focused on API production and formulation development. QDB is implemented into our R&D activities, including process design, optimization, scale ups. Our labs are equipped with modern instruments, and operations are guided by internal SOPs. 
Newelpharm & Biodeal is located in BioSciKin Park in Xuzhuang, Nanjing.  It occupies  square feet state-of-art laboratories; and employees 40 experienced and talented scientists. Newelpharm & Biodeal believes that R&D is the key for success, and innovation creates value.  Biodeal's strategy is to build a pipeline filled with generics and patent drugs for the treatment of cardiovascular, central nerve, inflammatory, antiviral, and cancer.  Our business is growing rapidly in both domestic and oversea markets.  To further expand our production capacity, Newelpharm & Biodeal is planning to build a cGMP manufacturing facility.  Our goal is to make high-quality products accessible to more people and more patients around the world.
In the past few years, Newelpharm & Biodeal has successfully cooperated with some strategic partners in marketing and sales in cancer, cardiovascular, inflammation, infection areas.